Relapse-free survival is progressively shortened in a subset of Black patients with immune-mediated TTP treated in the rituximab era

This study used the USTMA retrospective iTTP registry to evaluate relapse-free survival with successive courses of rituximab treatment, including differences observed among Black patients with iTTP.